Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 7UNKNOWN 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Colorectal Neoplasms 108Stomach Neoplasms 68Pancreatic Neoplasms 33Neoplasms 24Lymphoma, Large B-Cell, Diffuse 22Carcinoma, Non-Small-Cell Lung 21Neoplasm Metastasis 18Rectal Neoplasms 17Colonic Neoplasms 17Esophageal Neoplasms 16Parkinson Disease 4, Autosomal Dominant Lewy Body 13Adenocarcinoma 13Carcinoma, Hepatocellular 12Ovarian Neoplasms 10Biliary Tract Neoplasms 9Adenocarcinoma Of Esophagus 9Esophageal Squamous Cell Carcinoma 8Cholangiocarcinoma 8Gastrointestinal Neoplasms 7Lymphoma, Non-Hodgkin 6Endometrial Neoplasms 6Gallbladder Neoplasms 5Advanced Solid Tumors 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Carcinoma, Pancreatic Ductal 4Breast Neoplasms 4Advanced Solid Tumor 4Solid Tumors 3

Interventions

tislelizumab 2sugemalimab 2pegaspargase 2IMC-001 2Gemcitabine 2tipifarnib 1relatlimab 1ontuxizumab 1gemcitabine-oxaliplatin regimen 1camrelizumab 1WW Domain-Containing Oxidoreductase 1Vitamin B 12 1Sensitivity and Specificity 1Oxaliplatin 1Nivolumab 1Mannose-Binding Lectin 1Ice 1Folic Acid 1Commerce 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Extranodal NK-T-Cell × Oxaliplatin × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡